Hepatitis B, D, C, and HCC viruses in Tajikistan

Abdusamad Dustov* and Zebunisso Khakimova

*Correspondence: Abdusamad Dustov, Institute of Gastroenterology, Ministry of Health of the Republic of Tajikistan, E-mail: dustovsamad@gmail.com.

Received: 02 January 2018; Accepted: 14 February 2018

Keywords
Viral hepatitis, Tajikistan, Infection, Serological Testing.

Introduction
Hepatitis B virus (HBV) and hepatitis C virus (HCV) are common etiological agents of viral hepatitis. Approximately 350 million people are infected with HBV worldwide and the World Health Organization (WHO) estimates that approximately 170 million people are infected with HCV. Chronic HBV and/or HCV infection can progress to liver cirrhosis and hepatocellular carcinoma (HCC). HCV displays a high degree of genetic variability and is classified into six major genotypes that show sequence similarities of only 66-69% [1]. There has been no report on the prevalence of the hepatitis B and C viruses in Tajikistan. Therefore, the aim of the present study was to investigate prevalence viral hepatitis D and C among population and the genotypic prevalence and clinical significance of HCV, HBV, and/or HDV among chronic hepatitis patients with and without liver cirrhosis and/or HCC in Tajikistan. Furthermore, the association between coinfection patterns or HBV specific mutations and disease progression were also analyzed in this study.

Methods
Patients Sera were obtained from 124 consecutive chronic liver diseases patients over a period of 6 months between February to August 2008. Patients in this study were classified into two clinical groups (i) Chronic hepatitis: patients with constantly high serum alanine aminotransferase level (ALT), and (ii) Liver cirrhosis and HCC: patients, as diagnosed clinically based on ultrasonography, detection of serological tumor markers (AFP) and in a few cases histologically.

Serological Testing
Anti-HCV, HBsAg, HBeAg, anti-HBc and anti-HBs were determined by chemiluminescence with commercial assay kits (Fujirebio, Inc., Tokyo, Japan). HCV core antigen (HCVcAg), was measured [2], using enzyme immunoassay (Fujirebio, Inc.). Delta antibody (anti-HDV) was assessed only in HBsAg positive specimens using the recombinant HDV Ag [3] diagnostic kit ELISA Anti-HDV (RPC Diagnostics Systems, Nizhnyi Novgorod, Russia). Biochemical markers, that is, ALT, AST, Alkaline Phosphatase, cholesterol, bilirubin were measured in all samples at the local hospital. Genotyping of HCV Total RNA was extracted from serum, reverse transcribed into cDNA using random hexamer primer as described previously [4]. Confirmation of HCV RNA in the samples was carried by amplifying highly conserved 50UTR region and HCV genotypes were determined for both; structural (E1/Core) and nonstructural (NS5B) viral genes using either or both genotyping PCR [4,5] and/or direct sequencing with genotype-universal primers [6]. Screening for HCV Type RF1_2k/1b screening for natural recombinant type RF1_2k/1b strain was performed by the newly developed sensitive and specific method allowing detection up to 10 copies/assay (100 copies/ml) of the target sequence even if it is present in minority in mixed heterogeneous template. Briefly, the primers were designed to amplify a part of NS2 coding region between nt. 2986 and 3270 spanning the intergenotypic breakpoint described for RF1_2k/1b [7]. Target product’s size was 347 base pair (bp) in the first round of PCR and 300 bp in the second round of the “hemi-nested” PCR.

Genotyping of HBV and HDV
All of the HBsAg-positive samples were subjected to genotyping by commercial EIA kit (Institute of Immunology Co., Ltd, Tokyo, Japan). The method allows discrimination among the seven major HBV genotypes (A-G) by monoclonal antibodies targeted to the preS2 epitopes [8]. HBV DNA was extracted by QIAamp DNA Blood Mini Kit (Qiagen, Inc., Hilden, Germany) from 100 ml of all HBsAg-positive sera. Complete genome was successfully
The nucleotide sequence data reported in this paper will appear in the DDBJ/EMBL/GenBank nucleotide sequence databases with the accession number(s) AB330313 to AB330383.

Figure 1A: Phylogenetic analysis of the hepatitis C virus (HCV) partial E1 region, sequences from Tajikistan and other countries. Tajikistan isolates (e.g., TAJ74, TAJ75, etc.) were subject to bootstrap resampling with all available sequences in E1 region retrieved from the EMBL/DDBJ/GenBank database. Closest neighbors used for phylogenetic tree are indicated under the corresponding accession numbers from DDBJ/EMBL/GenBank. B: Phylogenetic analysis of the HCV partial NS5B region, sequences from Tajikistan and other countries. Tajikistan isolates (e.g., TAJ108, TAJ75, etc.) were subject to bootstrap resampling with all available sequences in NS5B region retrieved from the EMBL/DDBJ/GenBank database. Closest neighbors used for phylogenetic tree are indicated under the corresponding accession numbers from DDBJ/EMBL/GenBank.
In this study 15 out of 68 anti-HCV positive samples were negative for HCV RNA. The HCVcAg was positive in only 4 of the 15 cases, suggesting that HCV RNA was degraded in these samples, while remaining 11 cases had resolved acute HCV infection. HCV infection was found to be high in both groups (group 1.47.6% and group 2.42.5%). HCV RNA was detected in 91% of cases (100% in group 1 and 70.5% in group 2). Anti-HBc was found to be high in both groups (94% and 87.5%, respectively). Although seroprevalence of anti-HBs was very low (12.1%) in the studied population but significantly high in group 1 (16.6%) than group 2 (P<0.0356) while a few cases were positive for anti-HBeAg (2.9% and 5.8%, respectively). Positivity for HBsAg was regarded as indicating HBV infection.

The seroprevalence of HBsAg was equally high in both groups, that is, group 1.40.4% and group 2.42.5%, whereas DNA positivity was 70.5% and 76.4%, respectively. Overall anti-HDV seroprevalence was 23.5%, 12 out of 51 HBsAg positive cases, relatively higher in group 2 (35.2%) compared to group 1 (17.6%) P.0.05. HBV viremia was detected in 83.3% of cases (100% in group 1 and 66.6% in group 2) (Table 1). Based on the serological findings for hepatitis viruses, the patients were categorized into five groups, HCV only (40.3%), HBV only (21.7%), HCV/HBV (4.8%), HBV/HDV (9.7%), and HCV/HBV/HDV (0.8%) in Tajikistan (Table 1).
When the seropositivity of hepatitis markers was analyzed in relation to age (Figure 1), it was found that the prevalence of HBsAg was relatively high in younger group (<29 years old) and tended to decline with age. The opposite trend was observed in anti-HCV prevalence, which was increasing with the age of the patients. The seroprevalence of anti-HBc was high in all age groups, indicating that most patients had past HBV infection during childhood.

**HBV, HDV and HCV Genotypes**

HCV genotyping was carried by two independent methods, that is, by type specific primers for core, NS5B region and phylogenetic analyses based on nucleotide sequences in E1 or NS5B region. No discrepancy was observed among the results between either method (Figure 2A,B), however, one case (TAJ74) was determined as HCV genotype 2c (HCV/2c) only by the phylogenetic analysis in E1 region (Figure 2A). A total of 7.6% of cases were untypeable by one of either method (Table 2). Overall, HCV/1b was a predominant genotype (84.6%) in Tajikistan, followed by HCV/3a (7.6%), 2a (5.7%), and 2c (1.9%). None of the HCV-infected in this study carried recombinant 2k/1b strain. Other potential forms of recombination were also excluded by matching result of genotyping based on both structural and nonstructural genomic parts (Table 2). Interestingly, all 12 LC/HCC patients had HCV/1b, not 3a or 2a (Table 3). HBV genotype D (HBV/D) was the predominant genotype (94.1%) in both groups, that is, group 1=97% and group 2=88.2%, followed by genotype A (2.9% and 11.7%, respectively). HBV genotypes were determined in 45 (88%) of 51 HBsAg-positive cases by EIA. The entire HBV genome was sequenced successfully for seven cases (Figure 3), and the precore/core promoter region was sequenced in the other 25 cases. The remaining five cases were only positive by PCR for a short S region. The full genome analysis revealed that of the four HBV/D strains, two belonged to subgenotype D1, and the remaining two to subgenotype D2. All three HBV/A strains in this study were belonged to subgenotype Ae.

**Variability of HBV in Enhance II, Basal Core Promoter (BCP), Pre-C/C Region**

The prevalence of the nucleotide substitutions along the 33 sequence bearing the enhancer II/core promoter/ precore/core regions of the HBV genome are summarized for both clinical groups (22 group 1 vs. 11 group 2) in the Table 4. Due to the small numbers of patients with liver cirrhosis (n=8) and HCC (n=3), these were combined in the “Group 2” to enable the comparative analysis with chronic hepatitis patients without the complications; “Group 1.” The frequency of A1757 was high in both of the groups without the difference significant statistically. The T1762/A1764 double mutation was more frequent in the Group 2 and this was significant; P=0.0004. The difference in prevalence of the A1896, A1899, and T1912 mutations did not reach statistical significance between the groups.

**Discussion**

In the present study, the seroprevalence and molecular-heritic characteristics of the hepatitis viruses were investigated among chronic hepatitis (Group 1) and liver cirrhosis/HCC (Group 2) patients in Tajikistan. The HCV seroprevalence was equally high in both of the groups (47.6% and 42.5%, respectively) followed by HBsAg (40.4% and 42.5%, respectively). These results are slightly higher than the previous studies carried in neighboring Uzbekistan, where anti-HCV was detected in 26.8-41.9% and HBsAg in 25.6% of chronic hepatitis patients [12,13], such a difference may be explained by the different ages of studied patients different collecting time and also regional characteristics. A rather old study carried on the healthy population in Tajikistan and Azerbaijan showed that HBsAg detection was significantly higher in Tajikistan (7.2%) than in Azerbaijan (2.8%) suggesting that HBV is endemic in this country [14]. Tajikistan introduced universal immunization against HBV for newborn children since 2002. Although, new anti-viral drugs have the potential to alter the natural progression of disease but their high cost prevents the mass use of therapy in Tajikistan. One of the interesting observations in this study was the trend of seroprevalence of anti-HCV to increase and HBsAg do decrease with the age of the patients. Interestingly, the prevalence of anti-HBe was very high regardless the age of the patients, indicating that most of the patients had present or past infection of HBV.

The age-related decline of the HBsAg prevalence observed in this study may be explained by either; seroclearance of HBsAg due to natural seroconversion [15] or by death of the HBV-infected patients at age younger than those with HCV, due to earlier development of the end stage liver disease [16-18]. Alternatively, suppressive effect of the concurrent HCV infection might have caused the loss of the HBV antigenia [19-21]. HCV/1b has been found as the dominant genotype (84.6%) in Tajikistan, followed by 3a (7.6%), 2a (5.7%), and 2c (1.9%). The similar epidemiological situation was also described in the former Soviet Union Republics (Russia, Belarus, Moldova, and Uzbekistan) [13,22,23] as well as in most of Asian countries, namely Mongolia [24], Taiwan [25], China [26], and Japan [27] where genotype 1b was predominant. The HCV core antigen (HCVcAg) has significant correlation with HCVRNA [28,29]. In this study 15 out of the 68 anti-HCV positive simples, had the HCV RNA undetectable by PCR method, however only 4 of the 15 cases had the HCVcAg detectable, suggesting that the viral RNA has degraded in these samples prior study [30], while the remaining 11 cases may have had an acute HCV infection resolved in the past. HBV genotypes have a characteristic geographical distribution [31,32]. Particularly, genotype D is widespread, predominating in the Mediterranean area and in the Middle East region. Genotype A is present in Europe, India, Africa, and North America. The present results have shown that 94% of HBV isolates in Tajikistan belonged to genotype D and 5.8% to genotype A. Similar epidemiological situation was
observed in a previous study carried in Uzbekistan, where HBV/D found in 87% and HBV/A in 13% of HBV infected patients [33]. Complete genome analysis of the four HBV/D strains determined in present study allowed distinction into two subgenotypes; D1 and D2. Previous reports indicate that HBV/D subgenotypes have no specific geographical distribution; however strains from the Middle East mainly belong to subgenotype D1 and those from India, Russia and Europe to D2 [32]. No specific clustering was observed in Tajikistan strains, which is in agreement with previous observations regarding HBV/D molecular epidemiology. HBV genotype A has three major geographical clusters, the European-North American (Ae), the Afro-Asian (Aa) [34], and the Central African (Ac) [35]. The HBV genotype A strains isolated in this study were all belonged to the subgenotype Ae. Increasing evidence suggests that specific HBV genomic mutations may increase the risk of HCC in the patients infected chronically. Particularly, a high incidence of the T1762/A1764 double mutation was found among HBV/B or C infected Asian population [36] and with HBV/E infected African patients [37]. Similarly, in the present study, the frequency of the double mutation was significantly high in group 2 (6HBV/D and 2 HBV/A) as compared to group 1 (1HBV/D and 1HBV/A). In vitro studies [18,38], indicated that the T1762/A1764 mutants show enhanced replication and might be associated with high incidence of HCC. The prevalence of coinfection with HBV and HDV found to be relatively higher in group 2 compared to group 1 (15% vs. 7.1%), however the difference was not statistically significant possibly due to the small size of cases (P.0.1990). Previous studies have demonstrated that the coinfection with these viruses was also contributing in high HCC incidence in Mongolia [16]. It is concluded that HBV and HCV are the major cause of viral hepatitis in Tajikistan. Among HBV-infected patients, the T1762/A1764 mutations were associated with liver cirrhosis/HCC in this population. We have sent 60 blood samples from patients with hepatitis B and D to the CDC (Centers for Disease Control and Prevention) Atlanta, GA, USA. We have received data on the prevalence of the HBV and HDV genotype in Tajikistan, the work on our samples continues. Molecular genetic study of the HDV in Tajikistan has shown that HDV genotype 1 occurs in 96% (58/ 60 examined). According to this literature, HDV genotype 1 is found in Asia and in only 25% of these patients the antiviral therapy was successful [39].

References


